Amgen Inc.

Warning: file_get_contents( failed to open stream: HTTP request failed! HTTP/1.0 404 Not Found in /home3/mnadeemm/public_html/ on line 66

(%) Date:

Amgen Inc.

Amgen, Inc. (NASDAQ:AMGN) Growth Inflection Could Take Time To Play Out

Deutsche Bank believes external headwinds have impacted the company's ability to fully monetize these breakthroughs and hence contribute to the relatively modest current growth profile

Amgen, Inc. (AMGN) Biosimilar Manufacturing Is Not Trivial

MGN’s January 2017 agreement with DVA ensures that at least 90% of DVA’s erythropoiesis-stimulating agents (ESA) be supplied by Amgen, protecting its ESA volume through 2022. DVA controls ~1/3 of ESA market in the US

Amgen, Inc. (AMGN) Biosimilar Neulasta Receives CRL

The company noted that the CRLstems from the FDA's request for a reanalysis of a subset of subject samples from the 04 study with a modified, more sensitive immunogenicity assay

Amgen, Inc. (AMGN): Neulasta Is Different From Neupogen

The firm notes that Neulasta is a long-acting, pegylated form of filgrastim, and is sufficiently distinguished from Neupogen to warrant an Advisory Committee meeting for CHS-1701

Amgen, Inc. (AMGN): Increase In Serious Cardiovascular Events Gives Cause For Concern

A key unexpected finding of the ARCH study was the approximate 30% increase in relative risk of serious cardiovascular events for patients who received Evenity